191 related articles for article (PubMed ID: 9858242)
41. Bone marrow delta-aminolaevulinate synthase deficiency in a female with congenital sideroblastic anemia.
Buchanan GR; Bottomley SS; Nitschke R
Blood; 1980 Jan; 55(1):109-15. PubMed ID: 7350930
[TBL] [Abstract][Full Text] [Related]
42. X-linked sideroblastic anemia due to ALAS2 intron 1 enhancer element GATA-binding site mutations.
Campagna DR; de Bie CI; Schmitz-Abe K; Sweeney M; Sendamarai AK; Schmidt PJ; Heeney MM; Yntema HG; Kannengiesser C; Grandchamp B; Niemeyer CM; Knoers NV; Swart S; Marron G; van Wijk R; Raymakers RA; May A; Markianos K; Bottomley SS; Swinkels DW; Fleming MD
Am J Hematol; 2014 Mar; 89(3):315-9. PubMed ID: 24166784
[TBL] [Abstract][Full Text] [Related]
43. Anti-Correlation between the Dynamics of the Active Site Loop and C-Terminal Tail in Relation to the Homodimer Asymmetry of the Mouse Erythroid 5-Aminolevulinate Synthase.
Na I; Catena D; Kong MJ; Ferreira GC; Uversky VN
Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29958424
[TBL] [Abstract][Full Text] [Related]
44. [A novel mutation of the ALAS2 gene in a family with X-linked sideroblastic anemia].
Zhu P; Bu D
Zhonghua Xue Ye Xue Za Zhi; 2000 Sep; 21(9):478-81. PubMed ID: 11877024
[TBL] [Abstract][Full Text] [Related]
45. ALAS2 acts as a modifier gene in patients with congenital erythropoietic porphyria.
To-Figueras J; Ducamp S; Clayton J; Badenas C; Delaby C; Ged C; Lyoumi S; Gouya L; de Verneuil H; Beaumont C; Ferreira GC; Deybach JC; Herrero C; Puy H
Blood; 2011 Aug; 118(6):1443-51. PubMed ID: 21653323
[TBL] [Abstract][Full Text] [Related]
46. [Acquired, vitamin B6-responsive, primary sideroblastic anemia, an enzyme deficiency in heme synthesis].
Meier PJ; Giger U; Brändli O; Fehr J
Schweiz Med Wochenschr; 1981 Oct; 111(41):1533-5. PubMed ID: 7313623
[TBL] [Abstract][Full Text] [Related]
47. Raab SO, Haut A, Cartwright GE, Wintrobe MM. Pyridoxine-responsive anemia. Blood. 1961;18(3):285-302.
Blood; 2016 May; 127(20):2365. PubMed ID: 27207318
[No Abstract] [Full Text] [Related]
48. Identification of a novel erythroid-specific enhancer for the ALAS2 gene and its loss-of-function mutation which is associated with congenital sideroblastic anemia.
Kaneko K; Furuyama K; Fujiwara T; Kobayashi R; Ishida H; Harigae H; Shibahara S
Haematologica; 2014 Feb; 99(2):252-61. PubMed ID: 23935018
[TBL] [Abstract][Full Text] [Related]
49. Microcytic anemia in a pregnant woman: beyond iron deficiency.
Rollón N; Fernández-Jiménez MC; Moreno-Carralero MI; Murga-Fernández MJ; Morán-Jiménez MJ
Int J Hematol; 2015 May; 101(5):514-9. PubMed ID: 25547425
[TBL] [Abstract][Full Text] [Related]
50. Lack of efficacy of pyridoxine (vitamin B6) treatment in acquired idiopathic sideroblastic anaemia, including refractory anaemia with ring sideroblasts.
Baumann Kreuziger LM; Wolanskyj AP; Hanson CA; Steensma DP
Eur J Haematol; 2011 Jun; 86(6):512-6. PubMed ID: 21388451
[TBL] [Abstract][Full Text] [Related]
51. Gene symbol: ALAS2. Disease: sideroblastic anaemia.
Pereira JC; Gutiérrez EO; Ribeiro ML
Hum Genet; 2004 Nov; 115(6):533. PubMed ID: 15678587
[No Abstract] [Full Text] [Related]
52. Gene symbol: ALAS2. Disease: sideroblastic anaemia.
Gonçalves P; Pereira JC; Ribeiro ML
Hum Genet; 2004 Nov; 115(6):532. PubMed ID: 15678585
[No Abstract] [Full Text] [Related]
53. X-linked sideroblastic anaemia in a female fetus: a case report and a literature review.
Nzelu D; Shangaris P; Story L; Smith F; Piyasena C; Alamelu J; Elmakky A; Pelidis M; Mayhew R; Sankaran S
BMC Med Genomics; 2021 Dec; 14(1):296. PubMed ID: 34930268
[TBL] [Abstract][Full Text] [Related]
54. Gene symbol: ALAS2. Disease: sideroblastic anaemia.
Pereira JC; Gonçalves P; Cuhna E; Ribeiro ML
Hum Genet; 2004 Nov; 115(6):533. PubMed ID: 15678586
[No Abstract] [Full Text] [Related]
55. Absent phenotypic expression of X-linked sideroblastic anemia in one of 2 brothers with a novel ALAS2 mutation.
Cazzola M; May A; Bergamaschi G; Cerani P; Ferrillo S; Bishop DF
Blood; 2002 Dec; 100(12):4236-8. PubMed ID: 12393718
[TBL] [Abstract][Full Text] [Related]
56. X-linked sideroblastic anemia associated with a novel ALAS2 mutation and unfortunate skewed X-chromosome inactivation patterns.
Aivado M; Gattermann N; Rong A; Giagounidis AA; Prall WC; Czibere A; Hildebrandt B; Haas R; Bottomley SS
Blood Cells Mol Dis; 2006; 37(1):40-5. PubMed ID: 16735131
[TBL] [Abstract][Full Text] [Related]
57. GLRX5 mutations impair heme biosynthetic enzymes ALA synthase 2 and ferrochelatase in Human congenital sideroblastic anemia.
Daher R; Mansouri A; Martelli A; Bayart S; Manceau H; Callebaut I; Moulouel B; Gouya L; Puy H; Kannengiesser C; Karim Z
Mol Genet Metab; 2019 Nov; 128(3):342-351. PubMed ID: 30660387
[TBL] [Abstract][Full Text] [Related]
58. Lethal ALAS2 mutation in males X-linked sideroblastic anaemia.
Rose C; Callebaut I; Pascal L; Oudin C; Fournier M; Gouya L; Lambilliotte A; Kannengiesser C
Br J Haematol; 2017 Aug; 178(4):648-651. PubMed ID: 27292130
[No Abstract] [Full Text] [Related]
59. [Congenital sideroblastic anemia-a new family with identification of K156E mutation of ALAS2 gene and literature review].
Cui R; Xu Z; Qin T; Zhang Y; Xiao Z
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):142-6. PubMed ID: 24606657
[TBL] [Abstract][Full Text] [Related]
60. Novel human pathological mutations. Gene symbol: ALAS2. Disease: sideroblastic anaemia.
Pereira JC; Barbot J; Ribeiro ML
Hum Genet; 2009 Aug; 126(2):333. PubMed ID: 19693999
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
